Search

Your search keyword '"Pulley M"' showing total 62 results

Search Constraints

Start Over You searched for: Author "Pulley M" Remove constraint Author: "Pulley M"
62 results on '"Pulley M"'

Search Results

1. Electrodiagnostic subtyping in Guillain–Barré syndrome patients in the International Guillain–Barré Outcome Study

2. Comparing Four Medicines to Treat Pain from Cryptogenic Sensory Polyneuropathy—The PAIN-CONTRoLS Study

3. Current treatment practice of Guillain-Barré syndrome

4. ‘Minimal symptom expression’ in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab

5. Consistent improvement with eculizumab across muscle groups in myasthenia gravis

6. Original research: Second IVIg course in Guillain-Barré syndrome with poor prognosis: the non-randomised ISID study

8. Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab:subgroup analysis of REGAIN and its extension study

9. Intravenous immunoglobulin treatment for mild Guillain-Barré syndrome. An international observational study

10. International Guillain-Barré Syndrome Outcome Study

11. Current treatment practice of Guillain-Barré syndrome

12. Eculizumab Improves Fatigue in Refractory Generalized Myasthenia Gravis

13. ‘Minimal symptom expression’ in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab

14. Second IVIg course in Guillain-Barré syndrome with poor prognosis. The non-randomised ISID study

15. A Phase 2, Double-Blind, randomized, Dose-Ranging trial Of Reldesemtiv in patients with ALS

16. Minimal manifestation status and prednisone withdrawal in the MGTX trial

17. Correction to: Eculizumab improves fatigue in refractory generalized myasthenia gravis (Quality of Life Research, (2019), 28, 8, (2247-2254), 10.1007/s11136-019-02148-2)

18. International Guillain-Barré Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain-Barré syndrome

19. Randomized Trial of Thymectomy in Myasthenia Gravis

20. Randomized trial of thymectomy in myasthenia gravis

21. Randomized trial of thymectomy in myasthenia gravis

26. The Keyword Option in the Analytic Early Warning and Monitoring System

30. 505VP Safety and effectiveness of ravulizumab in gMG: evidence from a global registry.

31. Long-term safety and efficacy of eculizumab in generalized myasthenia gravis

32. A 40-week phase 2B randomized, multicenter, double-blind, placebo-controlled study evaluating the safety and efficacy of memantine in amyotrophic lateral sclerosis.

33. Loss of humeral immunity in childhood cancer survivors not having undergone hematopoietic stem cell transplantation.

34. Patient preference for virtual versus in-person visits in neuromuscular clinical practice.

35. Clinical Challenges of Acute Porphyria in the Young Adult.

36. A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of Reldesemtiv In Patients With ALS.

37. Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS): Bayesian Adaptive Comparative Effectiveness Randomized Trial.

38. Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial.

39. A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis.

40. Expression analysis of the AtMLO gene family encoding plant-specific seven-transmembrane domain proteins.

41. "Grass roots reform" Massachusetts-style.

42. Turmoil in the Twin Cities.

43. California debate brewing over full risk capitation contracts.

44. Washington State: a reform test site.

45. Is CALPERS (California Public Employees Retirement System) a HIPC (health insurance purchasing cooperative)?

46. Northern California: crucible of change.

48. Immunocytochemical expression of the endothelial barrier antigen (EBA) during brain angiogenesis.

49. The therapeutic potential of lymphokines in neoplastic disease.

50. Intravenous, intralesional and endolymphatic administration of lymphokines in human cancer.

Catalog

Books, media, physical & digital resources